Ferring Pharmaceuticals

In 2018, Ferring pharmaceutical company will complete construction of a new facility for production of sterile preparations for women's health and infertility treatment in Tatarstan. By 2021, the company also plans to implement project Sever on the base of KFU on production of active pharmaceutical ingredients with the use of enzymatic methods of organic synthesis, said Frederick Paulsen, Executive Director.

23 March 2018

Ferring Pharmaceuticals, a global biopharmaceutical company, and Pharmstandard PJSC, a Russian pharmaceutical major, have announced the start of their strategic partnership for integrated production of Traktocil (INN Atosiban) and Pabal (INN Carbetocinum) for treatment of miscarriages and prevention of postpartum hemorrhage.

In 2016 - 2018, Pharmstandard-UfaVITA plant in Ufa is to establish hi-tech aseptic production of comprehensive injectable drugs.

25 August 2016

Investor profile

Ferring Pharmaceuticals


Company's website: https://ferring.com/en/home

T: +41 58 301 00 00

Private Company

Contact: Mr. WayneAnderson, CEO

Ferring Pharmaceuticals is a biopharmaceutical company searching, developing and selling innovative products for protection of reproductive health, oncology, urology, gastroenterology and orthopedics. The company's R&D and production businesses share the same goal to create specialized drugs capable of fighting different diseases and pathologies using resources and functional capabilities of human organisms. Marketing, medical, retail and wholesale divisions of Ferring operate in circa 60 countries and are managed from the company’s HQ in Saint-Preux, Switzerland.